A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope
Duarte, California, United States
Hope RugoRecruiting - Ucsd Moores Cancer Center
La Jolla, California, United States
Rebecca ShatskyRecruiting - Anschutz Medical Center
Aurora, Colorado, United States
Recruiting - Uchicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States
Rita NandaRecruiting - Massachusetts General Hospital
Boston, Massachusetts, United States
Recruiting - Memorial Sloan Kettering Cancer Center
New York, New York, United States
Nour AbuhadraRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 Aug 2025
- Primary completion
- 31 May 2027
- Completion
- 31 May 2028
- Last update posted
- 17 Mar 2026
- Registered enrollment
- 52
- Registry id
- NCT06908928
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.